Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
A look at big oncology deals since 2016 finds outright success stories hard to come by.
A look at big oncology deals since 2016 suggests that there have been more duds than successes.
Work targeting mesothelin, and some other antigens that have hitherto disappointed, continues.
The group has approval for Amtagvi, but now faces the prospect of a solo launch.
Approval on the basis of Flaura2 is part of a double success for Astra's Tagrisso, which has also scored in Laura.